Oculis Holding AG (OCS)
12.94
-0.24
(-1.78%)
USD |
NASDAQ |
Aug 25, 16:00
12.94
0.00 (0.00%)
After-Hours: 19:59
Oculis Net Income (Quarterly) : -12.61M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -12.61M |
| March 31, 2026 | -36.82M |
| December 31, 2025 | -29.42M |
| September 30, 2025 | -21.06M |
| June 30, 2025 | -30.69M |
| March 31, 2025 | -36.95M |
| December 31, 2024 | -32.66M |
| September 30, 2024 | -23.30M |
| June 30, 2024 | -23.04M |
| March 31, 2024 | -18.41M |
| December 31, 2023 | -14.09M |
| Date | Value |
|---|---|
| September 30, 2023 | -19.71M |
| June 30, 2023 | -14.33M |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | -0.4511M |
| September 30, 2021 | 1.201M |
| June 30, 2021 | 0.4735M |
| March 31, 2021 | 0.2548M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Novartis AG | 3.259B |
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | -2.184M |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 12.61M |
| EPS Diluted (Quarterly) | -0.2059 |
| Enterprise Value | 533.73M |
| Earnings Yield | -13.59% |
| Normalized Earnings Yield | -14.01 |